Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03246529 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A Phase 3 study of Multiple Myeloma, sponsored by BioLineRx.
- Active
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 18
- Study locations
NCT03246529: Active Phase 3 study of Multiple Myeloma, sponsored by BioLineRx.
NCT03246529 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by BioLineRx. The registered enrollment target is 180 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (67% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03246529, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by BioLineRx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 18
- Study locations
Study Summary
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
Conditions Studied
Interventions
- DRUG BL-8040 1.25 mg/kg + G-CSF
- DRUG Placebo +G-CSF
Study Locations (18)
Other
- Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases - Budapest
- University of Debrecen - Debrecen
- Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele - Catania
- Presidio Ospedaliero Morelli Viale Europa - Reggio Calabria
- Hospital de La Santa Creu I Sant Pau - Barcelona
- Hospital University Ramon y Cajal - Madrid
- Hospital Universitario 12 de Octubre - Madrid
Florida
- University of Florida - Gainesville
- University of Miami - Miami
California
- UCLA Medical Center - Los Angeles
Illinois
- Loyola University Medical Center - Chicago
Maryland
- University of Maryland - Baltimore
Minnesota
- Mayo Clinic - Rochester
Missouri
- The Washington University School of Medicine - St Louis
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03246529
The ClinicalTrials.gov registry entry for NCT03246529 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (67% lower). The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which BL-8040 1.25 mg/kg + G-CSF is the first listed.
NCT03246529 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03246529 about?
NCT03246529 is a clinical study titled "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)". A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
What is the current status of trial NCT03246529?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2018-03-23. Estimated completion is 2029-09-30.
What conditions does trial NCT03246529 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03246529?
The interventions under investigation include: BL-8040 1.25 mg/kg + G-CSF (DRUG), Placebo +G-CSF (DRUG).
Who is sponsoring clinical trial NCT03246529?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03246529 being conducted?
This trial has 18 study locations across California, Florida, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.